Lumida
/QURE
⌘K
Uniqure NV

Uniqure NV

QURE
$44.51USD+0.09%+0.04 today

MARKET CAP

3.1B

P/E (TTM)

FWD P/E

DAY RANGE

$44 – $45

52W RANGE

$9
$72

AI Summary

Stalk
Buy NowMedium

QURE remains in a Stage 2 uptrend with price supported by rising EMAs. The recent shallow pullback into the 9/20 EMA zone has held support, favoring continuation. Medium-term structure is bullish above the rising 50 DMA with clear higher highs and lows, while short-term timing conditions align for a Buy Now entry on the EMA pullback despite overbought context.

  • AMT-130 BLA filed under accelerated pathway after 75% disease-slowing in 3-year trial.
  • $810M cash balance expected to fund operations through 2030, reducing dilution risk.
  • FDA indicates Phase 1-2 data may lack sufficient primary evidence, delaying BLA approval.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$524.0M$106.5M$15.8M$27.1M$16.1M
YoY %+1296.8%-79.7%-85.1%+71.2%-40.6%
P / Sales1.9x9.6x20.9x31.7x85.5x
EV / Sales1.2x9.6x45.0x46.6x119.4x
Gross Profit, Adj.$499.0M$103.1M$2.2M$8.8M$14.4M
YoY %+1230.2%-79.3%-97.9%+296.9%+63.9%
Margin %95.2%96.9%14.0%32.4%89.5%
EV / Gross Profit1.3x9.9x321.9x143.7x133.3x
EBITDA, Adj.$305.6M$-141.8M$-271.0M$-171.7M$-170.6M
YoY %+358.7%-146.4%-91.1%+36.7%+0.6%
Margin %58.3%-133.2%-1710.4%-633.0%-1059.7%
EV / EBITDA2.1x-7.2x-2.6x-7.4x-11.3x
EBIT$298.3M$-150.3M$-282.9M$-184.3M$-185.3M
YoY %+331.7%-150.4%-88.2%+34.8%-0.6%
Margin %56.9%-141.2%-1785.5%-679.6%-1151.4%
EV / EBIT2.1x-6.8x-2.5x-6.9x-10.4x
Net Income$329.6M$-126.8M$-308.5M$-239.6M$-199.0M
YoY %+363.6%-138.5%-143.3%+22.3%+16.9%
Net Margin62.9%-119.1%-1947.1%-883.4%-1236.0%
EPS (GAAP)$7.04-$2.71-$6.47-$4.92-$3.46
YoY %+350.5%-138.5%-138.7%+24.0%+29.7%